- Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS
- [Ad hoc announcement pursuant to Art. 53 LR] Roche’s Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study
- Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer's disease diagnosis
- Roche receives FDA approval for the first molecular test to screen for malaria in blood donors
- Assemblée générale 2024 de Roche
- Roche Generalversammlung 2024
- Roche Annual General Meeting 2024
- Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure reductions with zilebesiran when added to standard of care
- New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions across multiple foods in people with food allergies
- FDA approves Xolair as first and only medicine for children and adults with one or more food allergies
More ▼
Key statistics
On Thursday, Roche Holding AG (RO:SWX) closed at 236.80, 3.23% above its 52-week low of 229.40, set on Apr 08, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 237.60 |
---|---|
High | 238.40 |
Low | 235.40 |
Bid | 240.00 |
Offer | 240.00 |
Previous close | 236.80 |
Average volume | 36.64k |
---|---|
Shares outstanding | 809.25m |
Free float | 731.55m |
P/E (TTM) | 15.39 |
Market cap | 179.96bn CHF |
EPS (TTM) | 14.30 CHF |
Annual div (ADY) | 9.60 CHF |
---|---|
Annual div yield (ADY) | 4.04% |
Div ex-date | Mar 14 2024 |
Div pay-date | Mar 18 2024 |
Data delayed at least 15 minutes, as of Apr 18 2024 16:30 BST.
More ▼